🔎 Trials Near Me

Pradžia › Vilkligė › Texas

Vilkligė klinikiniai tyrimai Texas

26 tyrimai dėl Vilkligė ieško dalyvių vietose Texas.

Miestai Texas

Oficialus tyrimo tekstas (anglų kalba)

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  • Sl0044 50738, Bellaire
  • Sl0044 50781, El Paso
  • Sl0044 50673, Fort Worth
  • ir dar 6
Renkami dalyviai3 fazė
Amžius 16 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06617325

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  • Prolato Clinical Research Center, Houston
Renkami dalyviai2 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-10-01 · NCT05268289

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  • Amarillo Center for Clinical Research, Amarillo
  • Precision Comprehensive Clinical Research Solutions - Colleyville, Colleyville
  • Precision Comprehensive Clinical Research Solutions, Euless
  • ir dar 4
Renkami dalyviai2 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-10-01 · NCT07409181

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  • Novel Research LLC, Bellaire
  • Accurate Clinical Research, League City
  • Epic Medical Research, Red Oak
Renkami dalyviai3 fazė
Amžius nuo 12 iki 100 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06133972

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

  • Research Site, El Paso
  • Research Site, Houston
Renkami dalyviai3 fazė
Amžius nuo 5 iki 17 · Visoms lytims · Atnaujinta 2026-09-30 · NCT05835310

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  • Research Site, Austin
  • Research Site, Baytown
  • Research Site, Colleyville
  • ir dar 3
Renkami dalyviai3 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07430306

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  • Amarillo Medical Specialists Rheumatology, Amarillo
  • Amarillo Center for Clinical Research, Amarillo
  • Arthritis and Rheumatology Research Institute, Frisco
  • ir dar 5
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07438496

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • ir dar 2
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT03816345

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

  • Research Site, Allen
  • Research Site, Mesquite
Renkami dalyviai1 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-18 · NCT07201558

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

  • Baylor College of Medicine, Houston
Renkami dalyviai1 fazė
Amžius nuo 18 iki 60 · Visoms lytims · Atnaujinta 2026-09-14 · NCT06975787

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  • North Texas Center for Clinical Research, Frisco
  • Accurate Clinical Research, Humble
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-14 · NCT07355218

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

  • The University of Texas Southwestern Medical Center, Dallas
Renkami dalyviai2 fazė
Amžius nuo 12 iki 70 · Visoms lytims · Atnaujinta 2026-09-14 · NCT07570862

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  • Allen Arthritis, Allen
  • Arthritis and Rheumatology Research Institute PLLC, Allen
  • Arthritis Care of Texas, Corpus Christi
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-11 · NCT07332481

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  • Arthritis Care of Texas - Corpus Christi, Corpus Christi
  • Lone Star Arthritis & Rheumatology Associates, P.C., Denton
  • El Paso Medical Research Institute (MedResearch, Inc), El Paso
  • ir dar 1
Renkami dalyviaiStebimasis tyrimas
Amžius 16 ir vyresni · Visoms lytims · Atnaujinta 2026-09-03 · NCT07175285

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

  • University of Texas MD Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-08-26 · NCT06121297

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

  • Texas Transplant Institute, San Antonio
Renkami dalyviai2 fazė
Amžius nuo 12 iki 65 · Visoms lytims · Atnaujinta 2026-08-24 · NCT07053800

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

  • Integrative Rheumatology of South Texas - Harlingen /ID# 276458, Harlingen
Renkami dalyviai1 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-10 · NCT06977724

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

  • Rheumatology Care Center, PLLC, Bellaire
  • Texas Arthritis Center, El Paso
  • Novel Research, LLC., Houston
  • ir dar 3
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-07-30 · NCT07201129

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

  • Investigative Site, Allen
  • Investigative Site, Arlington
  • Investigative Site, Colleyville
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-07-27 · NCT07260877

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

  • Stryde Research, Plano
  • Tranquil Clinical Research, Webster
Renkami dalyviai1 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-06-05 · NCT06613360

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants

  • US04-0, Irving
  • US02-0, San Antonio
Renkami dalyviai1/2 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-06-02 · NCT06625671

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

  • M D Anderson Cancer Center, Houston
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-20 · NCT04751396

Lupus Landmark Study: A Prospective Registry and Biorepository

  • UT Southwestern Medical Center, Dallas
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 110 · Visoms lytims · Atnaujinta 2026-04-15 · NCT05934149

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-15 · NCT06434363

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

  • Climb Bio Investigative Site #100104, Allen
  • Climb Bio Investigative Site #100101, San Antonio
Renkami dalyviai1 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-03-27 · NCT07011043

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.